Peptide questions, checked carefully.Independent peptide information · Sources on every review · No sales · No dosing.
Browse peptidesTeriparatide

Evidence brief

Teriparatide

Written and source-checked by Anthony Treviso, founder of The Peptide Field.

Direct answer

FDA-approved products exist for specific osteoporosis populations.

An established osteoporosis medicine that can reduce fracture risk in defined groups. Its evidence does not apply to every fracture-healing claim.

How strong is the evidence?
Established
An official agency review or strong, repeated studies in people support one clear use. That evidence applies only to the product, people, and use we reviewed. It does not mean the product is safe or effective for everyone.
What evidence exists?
Approved human outcomes
Approved products have evidence from studies in people that measured health results for specific uses. This does not show that every product, person, or use has the same result.
Sports rules
Not assessed
No current sports-rule review is available.

Reviewed July 23, 2026. Sources and update notes are below.

No sales or dosing advice. This guide explains research. It was not independently medically reviewed, and it does not diagnose, prescribe, or recommend treatment.

Also known as Forteo · PTH 1-34 · recombinant human parathyroid hormone 1-34

Part of Bone peptide medicines

Words used here

outcome
what the study measured
randomized
assigned to study groups by chance
peptide
a short chain of amino acids
analog
a changed version made to act like another substance
amino acid
a small building block that makes peptides and proteins
More detailProduct and study details

01 · Evidence profile

Four questions about the evidence

Benefits in peopleDid people have a meaningful health benefit?
StrongSeveral reliable sources describe this clearly.

Randomized evidence supports vertebral and nonvertebral fracture-risk reduction in defined osteoporosis populations.

Body changes in peopleDid a study measure how it changed the body in people? This alone does not show a health benefit.
StrongSeveral reliable sources describe this clearly.

Bone-turnover, exposure, and product-specific pharmacology are well characterized.

Known risksHow much do studies tell us about risks in people?
StrongSeveral reliable sources describe this clearly.

Labels describe hypercalcemia, orthostatic hypotension, osteosarcoma risk factors, and other precautions.

Exact productHow certain are the product identity and quality?
StrongSeveral reliable sources describe this clearly.

High for authentic approved products used within the label.

02 · Identity

What it is

Teriparatide is a 34-amino-acid piece of human parathyroid hormone. It is used as a prescription medicine to help build bone in osteoporosis.

Scientific group: Parathyroid hormone analogue. This group name describes the type of molecule or body signal. It does not prove a benefit, safety, or approval.

03 · Exact product

The molecule is not the finished product.

Formulation: The finished product's ingredients and physical form. Route: How the product enters the body. Indication: The approved or studied use and group of people for a product.

Forteo

2024 label
Formulation
Prefilled delivery device
Route
Subcutaneous
Indication scope
Osteoporosis uses in the high-fracture-risk populations defined in the product label.
Open published FDA label ↗
Approved products
  • Forteo
  • approved teriparatide products
Approved or reviewed uses
  • Osteoporosis treatment in labeled high-fracture-risk populations

04 · Research results

What the research shows

What the evidence shows

Controlled trials and approved labeling support fewer spine and non-spine fractures in defined osteoporosis groups at high fracture risk.

What remains unknown

This evidence does not prove faster healing for every new fracture, universal benefit in athletes, or safety outside monitored prescription use.

Exact product

The evidence applies to specific approved products and groups of people. Teriparatide evidence concerns approved drug products and labeled osteoporosis populations, not every product called PTH 1-34 or every type of fracture.

05 · Claim check

Claims I checked

3 claims checked for this brief.

Clinical outcomesWhat a study measured about people's health, symptoms, or ability to function.

“Teriparatide reduces fracture risk in defined osteoporosis populations.”

Supported with scopeThe reviewed evidence supports this exact statement only in the situation described below.

The pivotal evidence and label support vertebral and nonvertebral fracture-risk reduction in studied high-risk populations.

Evidence used
Randomized human outcomes. This answer uses a study that assigned people to groups by chance and measured a health outcome.
Limits of this answer
Labeled osteoporosis populations at high fracture risk. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
Open the full claim record ↗
Performance and recoveryWhat research does or does not show about physical performance or recovery.

“Teriparatide is proven to heal every fracture faster.”

Not establishedThe reviewed evidence does not establish this statement. This does not prove it can never be true.

Fracture prevention and acute fracture healing are different endpoints, and trial results vary by fracture setting.

Evidence used
Randomized human outcomes. This answer uses a study that assigned people to groups by chance and measured a health outcome.
Limits of this answer
Acute fracture-healing outcomes across all fracture types. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
Open the full claim record ↗
SafetyWhat is known and not known about harm, warnings, and safety limits.

“Because teriparatide is a peptide, it has no serious risks.”

MisleadingThis statement leaves out a limit that changes its meaning.

The current label includes clinically important warnings, precautions, and population restrictions.

Evidence used
Regulatory or product record. This answer uses an official regulator record or a specific product label.
Limits of this answer
Approved teriparatide product use. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
Open the full claim record ↗

06 · Questions

Questions people ask about Teriparatide

Is Teriparatide FDA approved?

FDA-approved products exist for specific osteoporosis populations. Approved products identified: Forteo, approved teriparatide products.

Is Teriparatide banned in sport?

Not assessed. This editorial review did not determine sport eligibility. Athletes must check the current prohibited list, Global DRO, and their governing body. This status is not personal clearance to compete.

What does the evidence show for Teriparatide?

Controlled trials and approved labeling support fewer spine and non-spine fractures in defined osteoporosis groups at high fracture risk.

What is still unknown about Teriparatide?

This evidence does not prove faster healing for every new fracture, universal benefit in athletes, or safety outside monitored prescription use.

07 · Safety

Safety limits for this record

The label has important limits on duration, risk factors, calcium, and monitoring. No dose, injection, or off-label fracture-healing instructions are provided.

Sports rules · Not assessed

This editorial review did not determine sport eligibility. Athletes must check the current prohibited list, Global DRO, and their governing body.

No current sports-rule review is available.

Reviewed .Check current rules for tested sport ↗

08 · Sources

Read the sources

09 · Review history

Review history

Initial brief based on the current Forteo label and fracture-prevention trial record.

Written and source-checked by Anthony Treviso, founder of The Peptide Field.

Not independently medically reviewed. This page is not a dosing, sourcing, or treatment guide.